|
|
|
THE SHEINER/ROWLAND ADVANCED COURSE IN PHARMACOKINETICS/PHARMACODYNAMICS
Switzerland
Organised by:
Professor Leon Aarons
University of Manchester, England
A Workshop, presenting advanced aspects and applications of pharmacokinetics, pharmacodynamics and kinetic/dynamic data analysis in the medical and pharmaceutical sciences.
Research Interests
Population pharmacokinetics and pharmacodynamics Computer aided clinical trial
design Optimal design for population pharmacokinetic and pharmacodynamic studies.
Population pharmacokinetics and pharmacodynamics
Population pharmacokinetics (PK) and pharmacodynamics (PD) aims to investigate and
quantify PK/PD differences between patients. The sources of this variability include
genetics, demographic differences, drug-drug interactions and disease state. Having
identified sources of variability it is possible to provide rational dosage regimen
guidelines. Population PK/PD is a modelling discipline and we use a variety of Maximum
Likelihood and Bayesian techniques to perform the modelling. Current therapeutic
applications include malaria, paediatrics, anti-inflammatories and anti-cancer agents.
Computer aided clinical trial design
Computer aided clinical trial design (CATD) builds on population modelling and is a
model based technique in which future clinical trials are designed based on the
current state of knowledge using stochastic simulation techniques. The work is carried
out within CAPKR. The methodology has been applied to an anti-migraine drug.
Optimal design for population PK/PD studies
The use of optimal design techniques is an alternative to CATD and aims to minimise
parameter estimation error using various information criteria. Both frequentist and
Bayesian methods are being applied. This work is also being carried out in CAPKR and
we are currently working on both the methodology and developing software.
Members of the Statistical Modelling Researcher Group:
- Aris Doukoumedtzidis
- Ivan Matthews (Ph.D. Student)
- Sau Yan Amy Cheung (Ph.D. Student)
- Kayode Ogungbenro (Ph.D. student)
- Claire Edwards (part time Ph.D. student)
- Richard Mills (part time Ph.D. student)
Scientific Research Links:
CAPKR ( http://www.capkr.man.ac.uk/ )
Population Approach group Europe ( http://www.page-meeting.org/page/ )
NONMEM project group ( http://c255.ucsf.edu/nonmem0.html )
The BUGS project (Bayesian methods using Gibbs sampling)
( http://www.mrc-bsu.cam.ac.uk/bugs/ )
PharmPK (PK discussion group) ( http://www.boomer.org/pkin/ )
Biography
Prof Leon Aarons is a Professor and Director of Undergraduate
Studies in the School of Pharmacy and Pharmaceutical Sciences at the University of Manchester, UK. Following a postdoctoral fellowship at the School of Chemistry, University of Leeds, he came to Manchester in 1976.
His major research interests lie in the area of pharmacokinetics. He has a general interest in the subject as a whole but has a special interest in data analysis and interpretation. He collaborates with members of the pharmacokinetic group in Manchester and also with other scientists in industry and academia throughout Europe. His current activities revolve around population pharmacokinetics. People involved in the drug development process are becoming increasingly aware of the importance of studying the pharmacokinetic and pharmacodynamics of the drug in the population interest as soon as possible.
He is a member on various committees promoting research including the United Kingdom Pharmacokinetic Discussion Group and is a member of the management committee of COST B15.
He is Co-Editor of the Journal of Pharmacokinetics and Pharmacodynamics and Executive Editor of the British Journal of Clinical Pharmacology.
Publications
2005 - I. Gueorguieva, I.A. Nesterov, L. Aarons, M. Rowland. 'Uncertainty analysis in
pharmacokinetics and pharmacodynamics', Pharm.Res. 22. 1614-1626 (2005).
2004
- L. Aarons, C. Baxter, S. Gupta. 'Pharmacodynamics of controlled release verapamil in
patients with hypertension: an analysis using spline functions', Biopharm.Drug Dispos.
25, 219-225 (2004).
2003
- S. Callies, D.P. de Alwis, J.G. Wright, A Sandler, M. Burgess, L. Aarons. ' A population
pharmacokinetic model for doxorubicin and doxorubicinol in the presence of a novel MDR
modulator, zosuquidar trihydrochloride (LY335979)', Cancer Chemother.Pharmacol. 51,
107-118 (2003).
2002
- G. Graham, S. Gupta, L. Aarons. 'Determination of an optimal dosage regimen using a
Bayesian decision analysis of efficacy and adverse effect data',
J.Pharmacokin.Pharmacodyn. 29, 67-88 (2002).
2001
- N.D. Evans, K.R. Godfrey, M.J. Chapman, M.J. Chappell, L. Aarons, S.B. Duffull. 'An
identifiability analysis of a parent-
metabolite pharmacokinetic model for ivabradine', J.Pharmacokin.Pharmacodyn. 28, 93-105
(2001).
- I. Nestorov, G Graham, S. Duffull, L. Aarons, E. Fuseau, P. Coates. 'Modeling
and simulation for clinical trial design involving a categorical response: A phase II
case study with naratriptan', Pharm.Res. 18, 1210-1219 (2001).
|
Workshop Home Page
email irene.sung@pkworkshops.com
http://www.pkworkshops.org